Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Trial of Pazopanib in Combination With Escalating Doses of Radioactive 131I in Patients With Well-Differentiated Thyroid Carcinoma Refractory to Radioiodine, Despite Having Some Uptake

NCT01413113 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT01413113
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01413113 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Trial of Pazopanib in Combination With Escalating Doses of Radioactive 131I in Patients With Well-Differentiated Thyroid Carcinoma Refractory to Radioiodine, Despite Having Some Uptake
Lead sponsor
University of Washington
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2011
Completion date
October 31, 2015
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent thyroid cancer, stage iva follicular thyroid cancer, stage iva papillary thyroid cancer, stage ivb follicular thyroid cancer, stage ivb papillary thyroid cancer, stage ivc follicular thyroid cancer, stage ivc papillary thyroid cancer